Angiolab, Inc. (XKON:251280)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,185.00
-15.00 (-0.36%)
Last updated: Aug 1, 2025
-0.36%
Market Cap13.73B
Revenue702.62M
Net Income-1.19B
Shares Out3.28M
EPS-1,356.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume402
Average Volume839
Open4,010.00
Previous Close4,200.00
Day's Range4,005.00 - 4,185.00
52-Week Range3,715.00 - 9,200.00
Beta0.14
RSI46.95
Earnings Daten/a

About Aspen Technology

Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases. Its Phase I products consist of AL101-PSO for psoriasis. The company’s Phase II a clinical trial products include AL101- NASH for the treatment of non-alcoholic steatohepatitis; AL101-OME, for otitis media with effusion; and AL102-PDT for periodontitis. Its Phase II clinical trial products comprise AL101-AMD to treat age related muscular degeneration; and AL101-AOB for the treatment of abnormal obesity. In addition... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 251280
Full Company Profile

News

There is no news available yet.